Skip to content

Treatment of Bleeding piles with Unani medicine Majoon Teewaj

Clinical Validation of Unani Pharmacopoeial Formulation Majoon Teewaj in BawÄ?sÄ«r DÄ?miya (Bleeding Piles)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051895
Enrollment
220
Registered
2023-04-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K649- Unspecified hemorrhoids

Interventions

Intervention1: Majoon Teewaj: 5gm (semisolid) orally twice daily to be taken with water after meals for 42days Control Intervention1: NIL: NIL

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender in the age group of 18-65 years 2. Patients having Rectal bleeding with two or more of the following symptoms of Bleeding Piles Constipation Mucus discharge Rectal fullness or discomfort Anal Itching 3. Patients of Rectal bleeding diagnosed / confirmed by proctoscopy examination

Exclusion criteria

Exclusion criteria: 1. Patients below 18 & above 65 years of age 2. Advanced hemorrhoids requiring surgery i.e. 3rd & 4th degree hemorrhoids 3. Patients with anal fissure and fistula in-ano 4. Patients with rectal prolapse, rectal polyp and palpable abdominal mass 5. Known cases of Carcinoma, Inflammatory Bowel Disease (Ulcerative colitis, Crohnâ??s disease etc.) 6. Known cases of Anaemia, uncontrolled Diabetes mellitus, Chronic hepatic, renal or cardiac ailments 7. History of long-term medication 8. History of drug addiction 9. Pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
Improvement in sign and symptoms of BawÄ?sÄ«r DÄ?miya (NUMC: F-96) (Bleeding Piles)Timepoint: At baseline, day 14th, 28th and 42nd day

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: At baseline, 14th day and at the end of treatment

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026